title: Concomitant mycosis fungoides and vitiligo: how mycosis fungoides may contribute to melanocyte destruction.
abstract: BACKGROUND
  Few reports have described vitiligo developing in patients with cutaneous T-cell lymphoma (CTCL).
  
  
  OBJECTIVE
  We sought to identify possible factors that might predispose patients with CTCL to vitiligo.
  
  
  METHODS
  Patient demographics, CTCL disease characteristics and treatments were analyzed in 25 patients with CTCL who developed vitiligo. Cox proportional hazards modeling was used to identify associations of risk factors with the development of vitiligo.
  
  
  RESULTS
  Younger age, later CTCL disease stage (stages IIB-IV) and presence of a CD8+CD4- mycosis fungoides phenotype were associated with the development of vitiligo. After adjusting for disease stage, increased risk of vitiligo was associated with methotrexate and CD4 antibody therapies (although the total number of patients with these was small), while decreased risk was associated with nitrogen mustard and PUVA therapies.
  
  
  CONCLUSIONS
  No single feature was common to all of our patients, suggesting that multiple factors may contribute to the development of vitiligo in a patient-specific fashion.
authors: Department of Dermatology, University of Alabama at Birmingham, Birmingham, Ala., USA.
authors: Jennifer L
authors: JL
authors: Herrmann
authors: Erica
authors: E
authors: Syklawer
authors: Madeline
authors: M
authors: Tarrillion
authors: Madeleine
authors: M
authors: Duvic
authors: Lauren C
authors: LC
authors: Hughey
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D015704:CD4 Antigens / Q000032:analysis; D016827:CD8 Antigens / Q000032:analysis; D005260:Female; D006801:Humans; D008297:Male; D008466:Mechlorethamine / Q000627:therapeutic use; D008544:Melanocytes / Q000473:pathology*; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000150:complications* / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D011701:PUVA Therapy; D012307:Risk Factors; D013601:T-Lymphocytes / Q000737:chemistry; D014820:Vitiligo / Q000453:epidemiology / Q000209:etiology*
chemical_list: D000964:Antimetabolites, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D015704:CD4 Antigens; D016827:CD8 Antigens; D008466:Mechlorethamine; D008727:Methotrexate